{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_ixekizumab",
          "name": "Ixekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_austedo",
          "name": "Austedo"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 4
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_austedo",
          "type": "Drug",
          "label": "Austedo",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_IL17A",
          "type": "Target",
          "label": "IL-17A",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF_alpha",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_inflammation",
          "type": "Phenotype",
          "label": "Skin Inflammation Phenotype",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_acitretin",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Acitretin通过IL-17A调节免疫反应"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Adalimumab抑制TNF-alpha，减少炎症"
        },
        {
          "source": "drug_etanercept",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Etanercept靶向TNF-alpha，缓解炎症"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Infliximab通过抑制TNF-alpha发挥作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Secukinumab特异性抑制IL-17A"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Ixekizumab靶向IL-17A以改善症状"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate在炎症通路中有作用"
        },
        {
          "source": "drug_cyclosporine",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Cyclosporine通过抑制免疫系统缓解炎症"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Tildrakizumab靶向IL-17A有效"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Brodalumab靶向IL-17A以改善临床症状"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Ustekinumab抑制IL-17及IL-23"
        },
        {
          "source": "target_IL17A",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A在炎症反应通路中重要"
        },
        {
          "source": "target_TNF_alpha",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "TNF-alpha在炎症反应通路中关键"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症反应通路与病理状态关联"
        },
        {
          "source": "drug_acitretin",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Acitretin已用于治疗该状态"
        },
        {
          "source": "drug_adalimumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Adalimumab显示出疗效"
        },
        {
          "source": "drug_etanercept",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Etanercept用作治疗选项"
        },
        {
          "source": "drug_infliximab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Infliximab用于该病的治疗"
        },
        {
          "source": "drug_secukinumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Secukinumab治疗显示帮助"
        },
        {
          "source": "drug_ixekizumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "Ixekizumab在这一状态下得到了认可"
        },
        {
          "source": "drug_methotrexate",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Methotrexate用于治疗皮肤疾病"
        },
        {
          "source": "drug_cyclosporine",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Cyclosporine有时用于此类疾病"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "Tildrakizumab已显示效果"
        },
        {
          "source": "drug_brodalumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Brodalumab被探索用于此病症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Ustekinumab对相关症状有帮助"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物通过作用于炎症通路影响广泛性脓疱性银屑病",
        "confidence": "high"
      }
    ],
    "assumptions": [
      "各药物具有有效到达靶器官的能力"
    ],
    "uncertainties": [],
    "next_focus_for_pi": [
      "调查药物的长期效果及潜在安全性问题"
    ]
  }
}